Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed Plc Stock Exchange Release 26 May 2021 at 13.30, Helsinki
Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Robert Bosch Venture Capital GmbH (“RBVC”). According to the notification, the total holdings in Optomed shares and votes held by RBVC has decreased to below 5.00 % per cent of all of the registered shares in Optomed on 25 May 2021.
The total number of the Company’s registered shares amounts to 14,003,144 shares. Each share entitles to one vote.
The total position of RBVC subject to the notification:
% of shares and voting rights (total of A) | % of shares and voting rights through financial instruments (total of B) | Total of both in % (A+B) | |
Resulting situation on the date on which threshold was crossed or reached | 3.45 % | - | 3.45 % |
Position of previous notification (if applicable) | 7.90 % | - | 7.90 % |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of sharesISIN code | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) |
Indirect (SMA 9:6 ja 9:7) |
Direct (SMA 9:5) |
Indirect (SMA 9:6 ja 9:7) |
|
FI4000410881 | 482,473 | - | 3.45 % | - |
SUBTOTAL A | 482,473 | 3.45 % |
Information in relation to the person subject to the notification obligation as contained in the notification
The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
Robert Bosch Sechste Vermögensverwal-tungsgesellschaft mbH | 100 % | - | 100 % of Robert Bosch Venture Capital GmbH |
Robert Bosch GmbH | 100 % | - | 100 % of Robert Bosch Sechste Vermögens-verwaltungs-gesell-schaftmbH |
Robert Bosch Stiftung GmbH (charitable) | 93.99 % of shares, no voting rights | - | 93.99 % of shares of Robert Bosch GmbH |
Robert Bosch Industrietreuhand KG (performs the entrepreneurial ownership functions) | 93.17 % of voting rights, 0.01% of shares | 93.17 % of voting rights and 0.01% of shares of Robert Bosch GmbH |
Further enquiries
Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com, +358(0)50 562 4077.
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 56 international patents protecting the technology.